Proliferative Diabetic Retinopathy Market to Reach Roughly US$ 1,000 Million by 2026-end

Companies in the global proliferative diabetic retinopathy market are employing strategic initiatives that include product development, geographical expansion, acquisitions, and mergers. These strategies are likely to aid the market players in advancing their businesses and increasing their market footprint. For example, ThromboGenics initiated partnership with Novartis (Alcon) for assisting in commercialization and marketing activities of JETREA beyond the U.S.

Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=40637

On similar lines, Alimera initiated sales of ILLUVEN in the U.K. and Germany, in a bid to foray the European market. The initiative was primarily aimed at tapping new markets and boosting revenue generation of the company. A new report of Transparency Market Research has profiles key players making notable contribution to expansion of the global market for proliferative diabetic retinopathy, which include Pfizer, Inc., Genentech, Inc. (Roche Holdings), Merck KGaA, Allergan Plc, Santen Pharmaceutical Co., Ltd., Cipla, Ltd., Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Intas Pharmaceuticals Limited, and Novartis AG.

According to World Health Organization, number of people affected with diabetes has exceeded 400 Mn, in case of adults, in 2014. Additionally, global prevalence of diabetes doubled, rising at over 8% in adult population. The Department of Assistive and Rehabilitative Services (DARS) has reported that nearly 80% of the diabetic population was affected from diabetic retinopathy in 2013, with a notable portion of this percentile estimated to acquire the proliferative condition. These numbers are further poised to witness a rise in the years to come, driven by unhealthy consumption patterns and comfort-driven lifestyles of consumers worldwide. This will further have a robust impact on demand for treatment drugs apropos to proliferative diabetic retinopathy in the foreseeable future.

Enquiry for discount on this report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=40637

The report estimates the market to record a splendid rise over the forecast period 2017 to 2026. Nearly US$ 1,000 Mn worth of drugs for treatment of proliferative diabetic retinopathy are anticipated to be sold worldwide by 2026-end. Considered as a serious sight threatening ailment on account of long-term exposure to diabetes, diabetic retinopathy results into progressive retinal damage and affects retinal circulatory system. Extremity of the disease, which may lead to proliferative condition, determines the selection of effective therapeutic measure, thereby entailing requirement for intraocular injections, laser surgery, vitrectomy, or anti-VEGF drug prescriptions.

In terms of revenues, North America is likely to remain at the forefront of the global proliferative diabetic retinopathy, driven by supportive reimbursement policies offered by the government coupled with greater prevalence of diabetes in the region. Additionally, robust penetration of management drugs such as anti-VEGF drugs viz. Lucentis, Avastin, and Eylea, has further supported revenue generation from treatment of this disease in North America. Europe and Asia-Pacific excluding Japan are also likely to endure as significant revenue contributors to the global proliferative diabetic retinopathy market.

Anti-VEGF drugs are likely to remain preferred among various drug class utilized for treatment of proliferative diabetic retinopathy across the globe. Revenues from sales of anti-VEGF drugs are poised to reach approximately US$ 700 Mn by 2026-end. Although corticosteroids’ sales are expected to record an impressive expansion in the market, revenues from this drug class will continue to be sluggish.

Report Overview @ https://www.transparencymarketresearch.com/proliferative-diabetic-retinopathy-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

This release was published on openPR.